Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

The trial specifically focuses on adults with CF who genetically cannot benefit from cystic fibrosis transmembrane conductance regulator (CFTR) modulators.1 CF is a hereditary, lifelong disease ...

to introduce a healthy copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the cells of the lung. This method has already demonstrated high gene transfer efficiency ...

Update on evaluation of cystic fibrosis transmembrane conductance regulator modulator therapies and continued patient access (November 2023) Responding to the National Institute for Health and Care ...

Feb. 6, 2025 — Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life ...

Dr. Frank Mathias, Chief Executive Officer of OXB, said, "We are delighted that Boehringer Ingelheim is using OXB's proprietary lentiviral vector manufacturing technology, to produce lentiviral vector ...